A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions-MedSci.cn

A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions

Musicco, F; Lasala, R; Santoleri, F; Costantini, A; Abrate, P; Carretta, MT; Proli, EM; Romagnoli, A; Petragnani, N; De Vita, F; Zeuli, M; Vici, P; Sansone, M; Pasquantonio, M; La Malfa, A; Fulgenzio, C

Lasala, R (通讯作者)，Umberto I Hosp Corato, Hosp Pharm, Via Ruvo 108, I-70033 Corato, Italy.

Abstract

Objective Palbociclib, a highly selective reversible CDK4-6 kinase inhibitor, is indicated in combination with an aromatase inhibitor or in combinatio......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions

科室

工具

服务